You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Immunotherapy has transformed the treatment landscape for several solid tumors, yet many patients still do not respond or achieve lasting benefit.
Some cancers can avoid detection, develop resistance, return after treatment, or fail to respond to currently available immunotherapies. These challenges underscore the need for new ways to engage the immune system for difficult-to-treat tumors.
At Astellas, we are pioneering innovative new approaches to overcome these barriers, aiming to drive deeper, more durable responses and meaningfully extend survival for patients with cancer.
Drawing on decades of oncology experience, our ambition is to make immuno-oncology more precise, powerful and purposeful for some of the hardest-to treat cancers, including gastrointestinal, genitourinary and lung cancers.
We combine deep patient insights, cancer biology expertise and leadership in immune-engaging platforms to help the immune system more selectively target tumors that have historically been out of reach.
Our approach is guided by disciplined decisions on targets across multiple stages of the cancer immunity cycle, modalities, and the patients who may benefit most.
Our Immuno-Oncology pipeline spans differentiated and precision-driven modalities, including antibody drug conjugates (ADC’s) that draw on our ADC leadership, next-generation bispecific T-cell engagers and multi-specific biologics.
Each program expands expertise across our portfolio, strengthening target selection, modality design and immune activation, helping us bring the most promising science closer to patients.
Astellas’ lead Immuno-Oncology investigational program is ASP2138, a potential first-in-class treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer.
ASP2138 is a bispecific immune cell engager which builds on our expertise in delivering therapies targeting CLDN18.2 (a protein that is expressed on certain tumor cells) for stomach and GEJ cancers. It is designed to bind to CLDN18.2 and a type of white blood cell known as a CD3-positive T cell. By binding to both of these targets simultaneously, ASP2138 brings these T cells closer to CLDN18.2-expressing tumor cells and activates their anti-tumor action.
Please view our pipeline for Immuno-Oncology below. You can also access the full Astellas pipeline page here.
For everyone in the cancer community, the ultimate goal is cure, but no one scientist, company or organization can cure cancer alone. It requires spirited collaboration, a commitment to open exchange of expertise and bold exploration.
With the shared aim of revolutionizing outcomes for patients with cancer, we combine scientific excellence with renowned academic institutions, industry partners and networked innovation hubs to accelerate the specialized platform-based aspects of our strategy.
To learn more about how to collaborate with Astellas, please visit our Partnering page.
Astellas strives to match the best science and the best talent in order to deliver on our mission to turn innovative science into VALUE for patients. We encourage you to visit our Careers page to learn how you can join our work to turn innovative science into VALUE for patients.
